TEMOVATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TEMOVATE (TEMOVATE).
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit inflammatory mediators (prostaglandins, leukotrienes) and suppress immune response.
| Metabolism | Primarily hepatic via CYP3A4; metabolites are excreted in urine and feces. |
| Excretion | Primarily renal; less than 10% as unchanged drug, majority as metabolites. Fecal elimination is minimal (<5%). |
| Half-life | Terminal half-life approximately 36-54 hours, with clinical context indicating prolonged skin retention due to high lipophilicity and slow release from stratum corneum. |
| Protein binding | Extensive (>99%) binding to plasma proteins, including albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution not well characterized for topical administration due to limited systemic absorption; for iv data, Vd approximately 0.5-1 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Topical: Systemic bioavailability varies widely (1-5% in intact skin, up to 30-50% in inflamed or occluded skin). |
| Onset of Action | Topical: within 24-48 hours for reduction of inflammation and pruritus. |
| Duration of Action | Duration of action after single topical application lasts 1-2 weeks, but clinical improvement often requires daily application for 2-4 weeks; note that prolonged use may lead to tachyphylaxis. |
| Molecular Weight | 466.98 Da (clobetasol propionate) |
Apply a thin layer to affected skin areas twice daily (morning and evening). Maximum duration of treatment is 2 consecutive weeks. Do not use more than 50 g per week.
| Dosage form | SOLUTION |
| Renal impairment | No data available; no specific dose adjustment recommendations for renal impairment. |
| Liver impairment | No data available; caution advised in severe hepatic impairment due to potential for increased systemic absorption. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 12 years of age. For children 12 years and older, same adult dosing applies with caution (maximum 2 weeks, limited to small areas). |
| Geriatric use | Use with caution; apply sparingly to smallest affected area for shortest duration due to increased skin atrophy risk. |
| 1st trimester | Topical corticosteroids should be avoided in the first trimester unless clearly needed. Inadequate evidence of safety. |
| 2nd trimester | Use only if potential benefit justifies potential risk to the fetus. Avoid prolonged use on large areas. |
| 3rd trimester | Use only if clearly needed. Prolonged use may lead to low birth weight or adrenal suppression in the fetus. |
Clinical note
Comprehensive clinical and safety monograph for TEMOVATE (TEMOVATE).
| Placental transfer | Topical corticosteroids cross the placenta. Degree varies with potency, formulation, and skin integrity. Limited data for clobetasol; caution advised. |
| Breastfeeding | Not recommended during breastfeeding due to potential for systemic absorption and adverse effects on the infant, including growth suppression. Avoid application to breast area. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to clobetasol propionate or any component of the formulationUntreated bacterial, viral, or fungal infections at the application siteRosaceaPerioral dermatitis
| Precautions | Reversible HPA axis suppression with prolonged use or large surface area, Cushing's syndrome from systemic absorption, Local adverse reactions: skin atrophy, striae, telangiectasias, acneiform eruptions, Prolonged use may increase risk of secondary infections, Avoid use on face, groin, axillae, or under occlusive dressings unless directed |
| Food/Dietary | No known food interactions. Avoid excessive alcohol intake as it may exacerbate skin conditions or increase side effects like flushing. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Insufficient human data; animal studies show cleft palate and fetal growth retardation at topical doses. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: avoid if possible. Second/third trimesters: avoid prolonged use on large areas or occluded skin due to potential fetal HPA suppression. |
| Fetal Monitoring | Monitor maternal skin atrophy and HPA axis suppression (ACTH stimulation test recommended if used >2 weeks on large areas). In fetus: monitor fetal growth via ultrasound if prolonged use. |
| Fertility Effects | No human data; animal studies show no impact on fertility. Theoretical risk of hypothalamic-pituitary-adrenal axis suppression with high-dose exposure. |
| Clinical Pearls | TEMOVATE (clobetasol propionate) is a super-high-potency topical corticosteroid. Limit use to 2 consecutive weeks; do not exceed 50 g/week to minimize adrenal suppression. Avoid use on face, groin, or axillae due to increased absorption. Occlusion dressings can dramatically enhance absorption and should be used cautiously. Monitor for signs of HPA axis suppression with prolonged or widespread use. |
| Patient Advice | Apply a thin layer only to affected areas, usually twice daily. · Do not use for more than 2 weeks in a row unless directed by your doctor. · Avoid covering the treated area with bandages or wraps unless instructed. · Do not use on the face, underarms, or groin unless specifically told to. · Wash hands after application unless treating hands. · Avoid contact with eyes or open wounds. · Do not use for any skin condition other than that prescribed. · Report any signs of skin thinning, easy bruising, or persistent irritation. |